{"id":560365,"date":"2026-07-03T01:00:00","date_gmt":"2026-07-02T23:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/tirzepatide-versus-dulaglutide-in-t2d-with-ascvd\/"},"modified":"2026-07-09T18:05:00","modified_gmt":"2026-07-09T16:05:00","slug":"tirzepatide-versus-dulaglutide-in-t2d-with-ascvd","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/tirzepatide-versus-dulaglutide-in-t2d-with-ascvd\/","title":{"rendered":"Tirzepatide versus Dulaglutide in T2D with ASCVD"},"content":{"rendered":"\n

GLP-1 receptor agonists have established themselves in recent years as a class of drugs with cardiovascular protective effects in type 2 diabetes. For dulaglutide, the 2019 REWIND study showed that the drug reduces major cardiovascular events compared to placebo\u2014over a median follow-up period of 5.4 years, with about one-third of participants having established cardiovascular disease and the remainder having cardiovascular risk factors. Tirzepatide, a dual agonist of the GLP-1 and GIP receptors, had demonstrated a pronounced effect on blood glucose and body weight in the approval studies (SURPASS program). However, direct evidence of cardiovascular benefit in a specifically designed outcome study was still lacking. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

GLP-1 receptor agonists have established themselves in recent years as a class of drugs with cardiovascular protective effects in type 2 diabetes. For dulaglutide, the 2019 REWIND study showed that……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":560368,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"SURPASS-CVOT","footnotes":""},"category":[11548,11359,11508,11384,11297,11442,11503],"tags":[21334,72410],"powerkit_post_featured":[],"class_list":["post-560365","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-cardiology","category-education","category-endocrinology-and-diabetology","category-general-internal-medicine","category-pharmacology-and-toxicology","category-studies","tag-dulaglutide","tag-tirzepatide","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-20 12:13:36","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":560817,"slug":"tirzepatide-versus-dulaglutide-dans-le-dt2-associe-a-une-ascvd","post_title":"Tirz\u00e9patide versus dulaglutide dans le DT2 associ\u00e9 \u00e0 une ASCVD","href":"https:\/\/medizinonline.com\/fr\/tirzepatide-versus-dulaglutide-dans-le-dt2-associe-a-une-ascvd\/"},"it_IT":{"locale":"it_IT","id":560822,"slug":"tirzepatide-rispetto-a-dulaglutide-nel-diabete-di-tipo-2-con-ascvd","post_title":"Tirzepatide rispetto a dulaglutide nel diabete di tipo 2 con ASCVD","href":"https:\/\/medizinonline.com\/it\/tirzepatide-rispetto-a-dulaglutide-nel-diabete-di-tipo-2-con-ascvd\/"},"pt_PT":{"locale":"pt_PT","id":560827,"slug":"tirzepatida-versus-dulaglutida-na-diabetes-tipo-2-com-ascvd","post_title":"Tirzepatida versus dulaglutida na diabetes tipo 2 com ASCVD","href":"https:\/\/medizinonline.com\/pt-pt\/tirzepatida-versus-dulaglutida-na-diabetes-tipo-2-com-ascvd\/"},"es_ES":{"locale":"es_ES","id":560833,"slug":"tirzepatida-frente-a-dulaglutida-en-la-diabetes-tipo-2-con-ascvd","post_title":"Tirzepatida frente a dulaglutida en la diabetes tipo 2 con ASCVD","href":"https:\/\/medizinonline.com\/es\/tirzepatida-frente-a-dulaglutida-en-la-diabetes-tipo-2-con-ascvd\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/560365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=560365"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/560365\/revisions"}],"predecessor-version":[{"id":560369,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/560365\/revisions\/560369"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/560368"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=560365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=560365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=560365"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=560365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}